Markets
Carvana In Arizona
(Kevin Carter/Getty Images)

Carvana shares drive higher after the used car seller gets the green light from Wall Street

Morgan Stanley says the company’s growth is “more than just a phenomenon.”

Carvana shares jumped as much as 5% before losing some steam after Morgan Stanley’s Adam Jonas upgraded the company.

Carvana lets buyers shop, sell, and trade cars online, which can be delivered at home or picked up at an eight-story car vending machine, but has recently dealt with scrutiny from short sellers and regulators, the latter of which culminated in a $1.5 million settlement with the Connecticut Attorney General to settle consumer complaints about delays in title and registration documents.

Jonas moved the stock to “overweight” from “equal weight” and raised the price target to $280 from $260, suggesting a 31% leap from Monday’s close.

Jonas sees Carvana as a “unique opportunity” in auto retail and fleet fulfillment, especially after the stock’s recent dip. Last month, shares took a 12% hit despite a strong earnings report as the company’s wholesale business failed to meet analysts’ expectations. The miss raised doubts about whether the company could justify the triple-digit stock rally over the past year.

While initially concerned about Carvana’s heavy debt load, Jonas is more optimistic now thanks to its strong cash flow, which helps manage its $5.6 billion debt. While Carvana still faces risks from from having subprime auto credit, Jonas said the company has “proven profitable growth is more than just a temporary phenomenon.”

Carvana shares are up 143% over the past year.

More Markets

See all Markets
$8.5T

Analysts at consulting firm Pantheon Macroeconomics estimate that the stock market’s enthusiasm for all things AI has added some $8.5 trillion to aggregate US household wealth since late 2022. They wrote:

“The S&P 500 returned about 70% between the start of ChatGPT mania around the end of 2022 to the end of Q2 2025, with roughly half of those returns generated by the ‘magnificent seven’ tech stocks, a very rough proxy for the stock market boost from AI euphoria.

We estimate that translates into a lift to household wealth held in stocks of about $8.5T.”

As my colleague Luke Kawa recently wrote, stock market wealth seems to be underpinning US consumer spending, especially among the richest Americans. Some of that spending may retrench if AI is indeed a bubble — as some have recently mooted — and eventually pops.

markets

Serve Robotics spikes after announcing multiyear partnership with DoorDash for deliveries

Serve Robotics is spiking in early trading after the maker of sidewalk delivery robots and DoorDash announced a “multi-year strategic partnership to roll out autonomous robot vehicles across the US,” starting with Los Angeles.

Serve already does restaurant deliveries in Los Angeles (as well as Miami, Dallas, Chicago, and Atlanta) thanks to its partnership with Uber Eats.

DoorDash, for its part, already utilizes Coco Robotics to deliver food in Los Angeles and Chicago. Last week, it debuted its own delivery robot called “Dot,” which can operate on roads and sidewalks and is designed for suburban environments, per the company. Dot will initially be trialed in Tempe and Mesa, Arizona.

Read more: A day in the life of a Serve food-delivery robot

markets

Novo Nordisk to acquire liver disease drugmaker Akero Therapeutics for up to $5.2 billion

Novo Nordisk announced Thursdsay that it intends to acquire Akero Therapeutics for up to $5.2 billion.

Novo said it would pay $54 per share for Akero, a 15% premium to its $46.49 closing price in Wednesday, for a total of $4.7 billion.

Akero’s efruxifermin (EFX) treats a liver disease known as MASH, or metabolic dysfunction-associated steatohepatitis. The company is currently conducting late-stage trials of the drug. Shareholders will receive another $500 million if US regulators approve EFX to treat compensated cirrhosis brought about by MASH.

Akero rose about 18% in premarket trading.

Roche announced in September that it would buy another MASH drugmaker, 89bio, for $2.4 billion. GSK in July completed a $1.2 billion deal to license Boston Pharmaceuticals MASH drug.

Novo, the maker of Ozempic and Wegovy, has been struggling to spark sales growth amid increased competition from other weight-loss drugs and copycat versions of its drugs. The Danish drugmaker, which is down more than 30% for the year, slipped about 1% in premarket trading.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.